Pluristem Therapeutics (Nasdaq: PSTI)(TASE: PSTI), a Haifa Israel-based regenerative medicine company, reports significant results from ongoing treatment of COVID-19 patients with its biological therapeutic products. According to recent news, 75% of those COVID-19 patients treated by the company’s regenerative therapy were off any mechanical ventilation after 28 days of treatment.
Compassionate Use Programs in Israel and America
Under a compassionate use program in Israel, in addition to an FDA Single Patient Expanded Access Program in the United States, treated patients were in Intensive Care Units (ICU), on invasive mechanical ventilation and were suffering from Acute Respiratory Distress Syndrome (ARDS) at the time of treatment.
The Regenerative Therapy
The patients were treated with the company’s PLX cells. As of last week, a total of 18 patients were treated in Israel and in the U.S., of which 8 (1 in the U.S. and 7 in Israel) so far have completed a 28-day follow up period.
28-day follow up highlights for 8 patients treated with PLX cells
The survival rate of the 8 patients treated with PLX cells was 87.5%75% of the patients were off any mechanical ventilat...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).